Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of FG-4592 for the Treatment of Anemia in Chronic Kidney Disease Patients Not Receiving Dialysis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01750190
Recruitment Status : Completed
First Posted : December 17, 2012
Last Update Posted : November 18, 2019
Sponsor:
Collaborators:
Astellas Pharma Europe B.V.
AstraZeneca
Information provided by (Responsible Party):
FibroGen

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The purpose of this study is to determine whether FG-4592 is safe and effective in the treatment of anemia in chronic kidney disease patients who are not on dialysis.

Condition or disease Intervention/treatment Phase
CKD Anemia Drug: FG-4592 Drug: Placebo Phase 3

Detailed Description:
There is a screening period of up to 6 weeks, a variable treatment period for individual subjects. In order to complete the treatment period simultaneously for all study subjects, the minimum treatment duration may be less than 52 weeks, with a maximum treatment duration of up to 3 years after the last subject is randomized, and a post-treatment follow-up period of 4 weeks. Subjects were randomized in a 2:1 ratio to receive either roxadustat (FG-4592) or placebo in a double-blind manner.
Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 922 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 3, Randomized, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of FG-4592 for the Treatment of Anemia in Chronic Kidney Disease Patients Not on Dialysis
Study Start Date : November 2012
Actual Primary Completion Date : September 20, 2018
Actual Study Completion Date : September 20, 2018

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: FG-4592 (Double-blind, Three times a week)
Weight-based starting doses of 70mg or 100mg; dose adjustments to hemoglobin levels are allowed during the study.
 Drug: FG-4592
Oral
Other Name: Roxadustat; ASP1517; AZD9941
Placebo Comparator: Placebo (Double-blind, Three times a week)
Weight-based starting doses of 70mg or 100mg; dose adjustments to hemoglobin levels are allowed during the study.
 Drug: Placebo
Oral


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Efficacy of roxadustat (FG-4592) for the treatment of anemia correction and maintenance [ Time Frame: 52 weeks ]
    Efficacy of roxadustat (FG-4592) in achieving hemoglobin correction and maintenance (as defined in protocol) in CKD subjects not on dialysis


Secondary Outcome Measures :
  1. Effect of roxadustat (FG-4592) on serum lipid parameters [ Time Frame: 28 weeks ]
    Change in low-density lipoprotein (LDL) cholesterol.

  2. Effect of roxadustat (FG-4592) on patient reported outcomes [ Time Frame: 28 weeks ]
    Evaluate health-related quality of life benefits, as measured by the 36-Item Short Form Health Survey (SF-36)

  3. Evaluate the need for anemia rescue therapy, such as IV Iron, blood transfusion or injectable ESA [ Time Frame: 52 weeks ]
    Proportion of patients who received rescue therapy (composite of RBC transfusion, ESA use, and IV iron)

  4. Effect of roxadustat (FG-4592) on blood pressure [ Time Frame: 52 weeks ]
    Change in mean arterial pressure and effect on reducing hypertension

  5. Safety of roxadustat (FG-4592) [ Time Frame: Minimum of 52 weeks ]
    Adverse events, serious adverse events, vital signs, electrocardiograms and physical exams


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Chronic kidney disease, Stage 3, 4, or 5, not receiving dialysis
  • Anemia qualified by measurements of hemoglobin values during screening
  • Additional blood work must be in a safe range for study entry
  • Body weight 45 to 160 kg
  • Willingness to use contraception if of child-bearing potential

Exclusion Criteria:

  • Treatment with an erythropoiesis-stimulating agent (ESA) within 12 weeks prior to study participation
  • More than one dose of intravenous iron within 12 weeks prior to study participation
  • Blood transfusion within 8 weeks prior to study participation
  • Active infection
  • Chronic liver disease
  • Severe congestive heart failure, recent heart attack, stroke, seizure, or blood clot
  • Uncontrolled blood pressure within 2 weeks prior to study participation
  • Renal cell carcinoma
  • History of malignancy, including multiple myeloma or other myelodysplastic syndrome
  • Chronic inflammatory disease that could impact red blood cell production
  • Any prior organ transplant, or a scheduled organ transplantation
  • Anticipated elective surgery that is expected to lead to significant blood loss, or anticipated elective heart procedure
  • Gastrointestinal bleeding
  • Any prior treatment with FG-4592 or a HIF-PHI
  • Recent use of an investigational drug or treatment, or participation in an investigational study
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01750190


Locations
Show Show 145 study locations
Sponsors and Collaborators
FibroGen
Astellas Pharma Europe B.V.
AstraZeneca
Investigators
Layout table for investigator information
Study Chair: Peony Yu, MD FibroGen
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Layout table for additonal information
Responsible Party: FibroGen
ClinicalTrials.gov Identifier: NCT01750190    
Other Study ID Numbers: FGCL-4592-060
First Posted: December 17, 2012    Key Record Dates
Last Update Posted: November 18, 2019
Last Verified: November 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by FibroGen:
anemia
chronic kidney disease (CKD)
non-dialysis
Hemoglobin (Hb)
End-Stage Renal Disease
 erythropoeitin
ASP1517
erythropoeisis stimulating-agent
AZD9941
Additional relevant MeSH terms:
Layout table for MeSH terms
Kidney Diseases
Renal Insufficiency, Chronic
Anemia
 Hematologic Diseases
Urologic Diseases
Renal Insufficiency